Skip to main navigation Skip to search Skip to main content

Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway

  • Seung Hyun Shin
  • , Ga Young Lee
  • , Mingyu Lee
  • , Jengmin Kang
  • , Hyun Woo Shin
  • , Yang Sook Chun
  • , Jong Wan Park
  • Seoul National University

Research output: Contribution to journal › Article › peer-review

Abstract

Despite many efforts to develop hormone therapy and chemotherapy, no effective strategy to suppress prostate cancer metastasis has been established because the metastasis is not well understood. We here investigate a role of CBP/p300-interacting transactivator with E/D-rich carboxy-terminal domain-2 (CITED2) in prostate cancer metastasis. CITED2 is highly expressed in metastatic prostate cancer, and its expression is correlated with poor survival. The CITED2 gene is highly activated by ETS-related gene that is overexpressed due to chromosomal translocation. CITED2 acts as a molecular chaperone to guide PRMT5 and p300 to nucleolin, thereby activating nucleolin. Informatics and experimental data suggest that the CITED2–nucleolin axis is involved in prostate cancer metastasis. This axis stimulates cell migration through the epithelial–mesenchymal transition and promotes cancer metastasis in a xenograft mouse model. Our results suggest that CITED2 plays a metastasis-promoting role in prostate cancer and thus could be a target for preventing prostate cancer metastasis.

Original languageEnglish
Article number4113
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - 1 Dec 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway'. Together they form a unique fingerprint.

Cite this